Regulatory Affairs Syndicator

Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Sprycel, an oral inhibitor of multiple tyrosine kinases, for the treatment of adults in all phases of chronic myeloid leukaemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy, including Gleevec (imatinib